Clinical Trials Logo
  1. Home
  2. Cushing Disease
  3. NCT05971758

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

Cushing Disease Clinical Trial

Official title:
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

Clinical Trial Summary

Supported by the pre-clinical data (summarized in Research Strategy), the investigators propose that Fimepinostat is an ideal candidate drug in the treatment and intervention of patients with Cushing Disease. The investigators propose a pilot, short-term (4 weeks) phase II single-center study to demonstrate the safety and efficacy of Fimepinostat in the treatment of patients with de novo, persistent, and/or recurrent CD recruited at the University of California, Los Angeles. The trial will have a 2-arm design and will simultaneously examine two different doses of Fimepinostat. The study will allow the investigators to determine the efficacy and safety of these doses in the treatment of CD and guide dose selection for subsequent, larger studies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05971758
Study type Interventional
Source University of California, Los Angeles
Contact
Status Not yet recruiting
Phase Phase 2
Start date January 2024
Completion date January 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT02350153 - Cushing´s Disease Epidemiology in Sweden
Not yet recruiting NCT03297892 - Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015 N/A
Recruiting NCT05804669 - A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome Phase 1/Phase 2
Recruiting NCT03364803 - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Recruiting NCT03774446 - Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Phase 2
Completed NCT03080181 - Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Phase 4
Recruiting NCT03831958 - Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
Completed NCT01331239 - Safety and Efficacy of LCI699 in Cushing's Disease Patients Phase 2
Completed NCT04201444 - Hair Cortisol and Cushing's Disease N/A
Completed NCT02233335 - The Factors Associated With the Recurrence in Patients With Cushing Disease N/A
Recruiting NCT04374721 - Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders N/A
Recruiting NCT03974789 - Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms
Completed NCT03621280 - Open-label Treatment in Cushing's Syndrome Phase 3
Recruiting NCT04486859 - Postoperative Thrombosis Prevention in Patients With CD N/A
Completed NCT00171951 - Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease Phase 2
Recruiting NCT00001595 - An Investigation of Pituitary Tumors and Related Hypothalmic Disorders